Gland Pharma Limited announced the resignation of its Chief Executive Officer, Mr. Shyamakant Giri. Mr. Giri submitted his resignation on February 24, 2026, and the Board of Directors accepted it today, March 3, 2026, upon the recommendation of the Nomination and Remuneration Committee. Mr. Giri will cease to be the Chief Executive Officer and Key Management Personnel of the Company effective from the close of business hours on April 30, 2026. The Board of Directors expressed their sincere appreciation for Mr. Giri's leadership and contributions during his tenure as CEO. Details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the resignation letter dated February 24, 2026, are enclosed with the announcement.
